Advertisement

Supportive Care in Cancer

, Volume 25, Issue 1, pp 59–66 | Cite as

Venous thromboembolism treatment outcomes in cancer patients and effect of third-party payers on anticoagulant choice

  • Gary W. Jean
  • Katherine Kelly
  • Jennie Mathew
  • Eneko Larumbe
  • Randall Hughes
Original Article

Abstract

Purpose

The purpose of this study is to compare the rates of recurrent VTE among cancer patients treated with parenteral agents to the oral anticoagulants.

Methods

This single-center study was a retrospective chart review of cancer patients with recurrent VTE between January 1, 2009 and December 31, 2014. The primary outcome of the study is the rate of recurrent VTE in patients who received a parenteral anticoagulant (enoxaparin, dalteparin, fondaparinux) versus those who received oral anticoagulants (warfarin and rivaroxaban). Other outcomes investigated include risk factors associated with recurrent VTE events and influence of third-party payer on anticoagulant selection.

Results

Four hundred fifty-seven patients met inclusion criteria (178 in the oral anticoagulant group and 279 in the parenteral anticoagulant group). Patients with Medicare were more likely to have received an oral anticoagulant (P = 0.003) and patients with private insurance were more likely to have received a parenteral anticoagulant (P = 0.004). There were 23 recurrent VTE events, 12 events (6.7 %) in the oral anticoagulant group and 11 events (3.94 %) in the parenteral group (P = 0.182). The only significant risk factor noted to increase risk of recurrent VTE was the presence of an IVC filter (adjusted OR 4.38, 95 % CI 1.67–11.53, P = 0.003).

Conclusions

While there is no statistical difference in VTE events between groups, the oral anticoagulant group numerically had a higher rate. Important associations were found to have an influence on anticoagulant selection and risk of recurrent VTE. These factors must be incorporated into decision making when treating cancer patients with VTE.

Keywords

Cancer-associated venous thromboembolism Anticoagulation management Warfarin Low molecular weight heparin Third-party payer 

Notes

Acknowledgments

This study is supported in part by the Texas Tech Health Sciences Center Clinical Research Institute. We would like to thank Lida Binesheian and Yasmine Alhasan for their assistance in data collection and chart review.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9(7):e1001275. doi: 10.1371/journal.pmed.1001275 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632–634. doi: 10.1111/j.1538-7836.2007.02374.x CrossRefPubMedGoogle Scholar
  3. 3.
    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846–1850. doi: 10.1056/NEJM200012213432504 CrossRefPubMedGoogle Scholar
  4. 4.
    Lee A, Khorana A (2015) Cancer associated thrombosis. In: DeVita VT, Lawrence TS, Rosenberg SA (eds) Cancer principles & practice of oncology, 10th edn. Wolters Kluwer Health, Pennsylvania, pp. 1969–1975Google Scholar
  5. 5.
    Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A, American Society of Clinical Oncology Clinical P (2013) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol 31(17):2189–2204. doi: 10.1200/JCO.2013.49.1118 CrossRefGoogle Scholar
  6. 6.
    Imberti D, Agnelli G, Ageno W, Moia M, Palareti G, Pistelli R, Rossi R, Verso M, Investigators M (2008) Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica 93(2):273–278. doi: 10.3324/haematol.11458 CrossRefPubMedGoogle Scholar
  7. 7.
    Akl EA, Kahale L, Barba M, Neumann I, Labedi N, Terrenato I, Sperati F, Muti P, Schunemann H (2014) Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. The Cochrane database of systematic reviews 7:CD006650. doi: 10.1002/14651858.CD006650.pub4 Google Scholar
  8. 8.
    Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G (2015) Assessing patients’ anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica 100(11):1486–1492. doi: 10.3324/haematol.2015.127126 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JR, Wells P, Woller SC, Moores L (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352. doi: 10.1016/j.chest.2015.11.026 CrossRefPubMedGoogle Scholar
  10. 10.
    Seaman S, Nelson A, Noble S (2014) Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adher 8:453–461. doi: 10.2147/PPA.S58595 Google Scholar
  11. 11.
    Noble SI, Finlay IG (2005) Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 19(3):197–201CrossRefPubMedGoogle Scholar
  12. 12.
    Rose AJ, Sharman JP, Ozonoff A, Henault LE, Hylek EM (2007) Effectiveness of warfarin among patients with cancer. J Gen Intern Med 22(7):997–1002. doi: 10.1007/s11606-007-0228-y CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ansell JE (2016) Reversing the effect of oral anticoagulant drugs: established and newer options. American journal of cardiovascular drugs : drugs, devices, and other interventions. doi: 10.1007/s40256-016-0162-7 PubMedGoogle Scholar
  14. 14.
    Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Bl D, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510. doi: 10.1056/NEJMoa1007903 CrossRefPubMedGoogle Scholar
  15. 15.
    Buller HR, Prins MH, Lensing AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297. doi: 10.1056/NEJMoa1113572 CrossRefPubMedGoogle Scholar
  16. 16.
    Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352. doi: 10.1056/NEJMoa0906598 CrossRefPubMedGoogle Scholar
  17. 17.
    Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808. doi: 10.1056/NEJMoa1302507 CrossRefPubMedGoogle Scholar
  18. 18.
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer I (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153. doi: 10.1056/NEJMoa025313 CrossRefPubMedGoogle Scholar
  19. 19.
    Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415. doi: 10.1056/NEJMoa1306638 CrossRefGoogle Scholar
  20. 20.
    Cohen RA, Villarroel MA (2015) Strategies used by adults to reduce their prescription drug costs: United States, 2013. NCHS data brief, no 184. National Center for Health Statistics, Hyattsville http://www.cdc.gov/nchs/data/databriefs/db184.pdf. Accessed 7 March 2016Google Scholar
  21. 21.
    Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA, Investigators C (2015) Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314(7):677–686. doi: 10.1001/jama.2015.9243 CrossRefPubMedGoogle Scholar
  22. 22.
    Group PS (2005) Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 112(3):416–422. doi: 10.1161/CIRCULATIONAHA.104.512834 CrossRefGoogle Scholar
  23. 23.
    Mansour A, Ismael Y, Abdel-Razeq H (2014) Inferior vena cava filters in patients with advanced-stage cancer. Hematology/oncology and stem cell therapy 7(4):136–141. doi: 10.1016/j.hemonc.2014.09.005 CrossRefPubMedGoogle Scholar
  24. 24.
    Schunn C, Schunn GB, Hobbs G, Vona-Davis LC, Waheed U (2006) Inferior vena cava filter placement in late-stage cancer. Vasc Endovasc Surg 40(4):287–294. doi: 10.1177/1538574406291821 CrossRefGoogle Scholar
  25. 25.
    Barginear MF, Lesser M, Akerman ML, Strakhan M, Shapira I, Bradley T, Budman DR (2009) Need for inferior vena cava filters in cancer patients: a surrogate marker for poor outcome. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 15(3):263–269. doi: 10.1177/1076029608315165 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Gary W. Jean
    • 1
  • Katherine Kelly
    • 2
  • Jennie Mathew
    • 3
  • Eneko Larumbe
    • 4
  • Randall Hughes
    • 5
  1. 1.DallasUSA
  2. 2.VA North Texas Health Care SystemDallasUSA
  3. 3.DallasUSA
  4. 4.LubbockUSA
  5. 5.University of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations